Cargando…
Potential Markers in Cardiac Hypertrophy?
Cardiomyopathies are diagnosed based on medical history of patient (symptoms and family history), physical examination, results of echocardiogram and in some situations additionally ECG or chest-X-ray results. Currently used non-invasive diagnostic methods, could be complemented by biochemical tests...
Autores principales: | Malinowski, Bartosz, Fulgheri, Gabriele, Wicinski, Michal, Grzesk, Elzbieta, Odrowaz-Sypniewska, Grazyna, Grześk, Grzegorz, Darwish, Nasser |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
The Communications and Publications Division (CPD) of the IFCC
2012
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4975242/ https://www.ncbi.nlm.nih.gov/pubmed/27683411 |
Ejemplares similares
-
Resveratrol Increases Serum BDNF Concentrations and Reduces Vascular Smooth Muscle Cells Contractility via a NOS-3-Independent Mechanism
por: Wiciński, Michał, et al.
Publicado: (2017) -
Pentraxin 3 as a Novel Marker in Cardiovascular Diseases?
por: Malinowski, Bartosz, et al.
Publicado: (2011) -
PCSK9 signaling pathways and their potential importance in clinical practice
por: Wiciński, Michał, et al.
Publicado: (2017) -
The Modulatory Effect of Ischemia and Reperfusion on Arginine Vasopressin-Induced Arterial Reactions
por: Szadujkis-Szadurska, Katarzyna, et al.
Publicado: (2016) -
Therapeutic Drug Monitoring of Carbamazepine: A 20-Year Observational Study
por: Grześk, Grzegorz, et al.
Publicado: (2021)